Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 10, 2010, Pages 1265-1276

  Scheen, André J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

DPP IV inhibitor; Metformin pharmacokinetics; Sitagliptin; Type 2 diabetes mellitus

Indexed keywords

EXENDIN 4; GLIPIZIDE; GLUCOSE; LIRAGLUTIDE; METFORMIN; METFORMIN PLUS SITAGLIPTIN; PLACEBO; SITAGLIPTIN;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADD ON THERAPY; ANOREXIA; AREA UNDER THE CURVE; CLINICAL TRIAL; CONTACT DERMATITIS; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; ISCHEMIC HEART DISEASE; LACTIC ACIDOSIS; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PATIENT COMPLIANCE; REVIEW; RHINOPHARYNGITIS; SINGLE DRUG DOSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG INTERACTIONS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; PYRAZINES; TRIAZOLES;

EID: 77956805536     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2010.513699     Document Type: Review

References (77)

1. DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-795
2. Scheen AJ, Lefebvre PJ. Oral antidiabetic agents: a guide to selection. Drugs 1998;55:225-236
3. Scheen AJ. Current management of coexisting obesity and type 2 diabetes. Drugs 2003;63:1165-1184
4. Howlett H, Porte F, Allavoine T, et al. The development of an oral antidiabetic combination tablet: design, evaluation and clinical benefits for patients with type 2 diabetes. Curr Med Res Opin 2003;19:218-225
5. Stumvoll M, Haring HU, Matthaei S. Metformin. Endocr Res 2007;32:39-57
6. Hundal RS, Inzucchi SE. Metformin: new understandings, new uses. Drugs 2003;63:1879-1894
7. Setter SM, Iltz JL, Thams J, Campbell RK. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy. Clin Ther 2003;25:2991-3026
8. Consoli A, Gomis R, Halimi S, et al. Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications. Diabetes Metab 2004;30:509-516
9. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009;52:17-30
10. Scheen AJ, Lefebvre PJ. Antihyperglycaemic agents. Drug interactions of clinical importance. Drug Safety 1995;12:32-45
11. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokin 1996;30:359-371
12. Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents: an update. Drug Safety 2005;28:601-631
13. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705
14. Ahren B. Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes. Expert Opin Emerg Drugs 2008;13:593-607
15. Lyseng-Williamson KA. Sitagliptin. Drugs 2007;67:587-597
16. European Medicines Agency (EMEA): Januvia (sitagliptin) - European Public Assessment Report (EPAR) - Scientific Discussion; 2007. Available from: http:// www.emea.europa.eu/humandocs/PDFs/ EPAR/januvia/H-722-en6.pdf [Last accessed 9 February 2010]
17. Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes. Expert Opin Pharmacother 2008;9:1705-1720
18. Dhillon S. Sitagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2010;70:489-512
19. Ahren B. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin - diabetes control and potential adverse events. Best Pract Res Clin Endocrinol Metab 2009;23:487-498
20. Ahren B. Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin. Vasc Health Risk Manag 2008;4:383-394
21. Scheen AJ, Radermecker RP. Addition of incretin therapy to metformin in type 2 diabetes. Lancet 2010;375:1410-1412
22. Gagliardino JJ, Santoro S, Arellano S, Di Girolamo G. New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin. Expert Opin Pharmacother 2008;9:1495-1507
23. Gallwitz B. Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes. Drugs Today (Barc) 2007;43:681-689 (Pubitemid 350220792)
24. Reynolds JK, Neumiller JJ, Campbell RK. Janumet: a combination product suitable for use in patients with Type 2 diabetes. Expert Opin Invest Drugs 2008;17:1559-1565
25. Green J, Feinglos M. New combination treatments in the management of diabetes: focus on sitagliptin-metformin. Vasc Health Risk Manag 2008;4:743-751
26. EMEA Janumet Assessment Report. Available from: www.ema.europa.eu/ humandocs/PDFs/EPAR/janumet/ H-861-en6.pdf
27. Halimi S, Schweizer A, Minic B, et al. Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet. Vasc Health Risk Manag 2008;4:481-492
28. He YL, Paladini S, Sabia H, et al. Bioequivalence of vildagliptin/ metformin fixed-dose combination tablets and a free combination of vildagliptin and metformin in healthy subjects. Int J Clin Pharmacol Ther 2008;46:259-267
29. Sambol NC, Brookes LG, Chiang J, et al. Food intake and dosage level, but not tablet vs solution dosage form, affect the absorption of metformin HCl in man. Br J Clin Pharmacol 1996;42:510-512
30. Timmins P, Donahue S, Meeker J, Marathe P. Steady-state pharmacokinetics of a novel extended-release metformin formulation. Clin Pharmacokinet 2005;44:721-729
31. Cullen E, Liao J, Lukacsko P, et al. Pharmacokinetics and dose proportionality of extended-release metformin following administration of 1000, 1500, 2000 and 2500 mg in healthy volunteers. Biopharm Drug Dispos 2004;25:261-263
32. Schwartz S, Fonseca V, Berner B, et al. Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care 2006;29:759-764
33. Choi MK, Song IS. Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet 2008;23:243-253
34. Pacanowski MA, Hopley CW, Aquilante CL. Interindividual variability in oral antidiabetic drug disposition and response: the role of drug transporter polymorphisms. Expert Opin Drug Metab Toxicol 2008;4:529-544
35. Wang DS, Jonker JW, Kato Y, et al. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther 2002;302:510-515 (Pubitemid 34787213)
36. Kimura N, Masuda S, Tanihara Y, et al. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet 2005;20:379-386
37. Atanasova I, Bozhinova K, Todorova D, Terziivanov D. Pharmacokinetics and comparative bioavailability of two metformin formulations after single-dose administration in healthy subjects. Clin Drug Investig 2003;23:743-749
38. Hermann LS, Schersten B, Melander A. Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination. Diabet Med 1994;11:953-960
39. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995;333:541-549
40. Takane H, Shikata E, Otsubo K, et al. Polymorphism in human organic cation transporters and metformin action. Pharmacogenomics 2008;9:415-422
41. Shikata E, Yamamoto R, Takane H, et al. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J Hum Genet 2007;52:117-122
42. Shu Y, Brown C, Castro RA, et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther 2008;83:273-280
43. Shu Y, Sheardown SA, Brown C, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007;117:1422-1431
44. Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010;12:648-658
45. Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet 2010;49:573-588
46. Vincent SH, Reed JR, Bergman AJ, et al. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C] sitagliptin in humans. Drug Metab Dispos 2007;35:533-538
47. Bergman AJ, Stevens C, Zhou Y, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 2006;28:55-72
48. Herman GA, Bergman A, Liu F, et al. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol 2006;46:876-886
49. Herman GA, Stevens C, Van Dyck K, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005;78:675-688
50. Scheen AJ. Current management strategies for coexisting diabetes mellitus and obesity. Drugs 2003;63:1165-1184
51. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006;91:4612-4619
52. Herman GA, Bergman A, Yi B, et al. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Curr Med Res Opin 2006;22:1939-1947 (Pubitemid 44663399)
53. Bergman AJ, Cote J, Yi B, et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 2007;30:1862-1864
54. Chan JC, Scott R, Arjona Ferreira JC, et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008;10:545-555
55. Migoya EM, Stevens CH, Bergman AJ, et al. Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin. Can J Clin Pharmacol 2009;16:e165-70
56. Williams-Herman D, Engel SS, Round E, et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord 2010;10:7
57. Mannucci E, Ognibene A, Cremasco F, et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 2001;24:489-494
58. Mannucci E, Tesi F, Bardini G, et al. Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes. Diabetes Nutr Metab 2004;17:336-342
59. Migoya EM, Miller J, Larson P, et al. Sitagliptin, a selective DPP-4 inhibitor, and metformin have complementary effects to increase active GLP-1 concentrations [abstract]. Diabetes 2007;56(Suppl 1):A74
60. Hinke SA, Kuhn-Wache K, Hoffmann T, et al. Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem Biophys Res Commun 2002;291:1302-1308
61. Brazg R, Xu L, Dalla Man C, et al. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2007;9:186-193
62. Arnolds S, Dellweg S, Clair J, et al. Further improvement in postprandial glucose control when adding exenatide (EXE) or sitagliptin (SITA) to combination therapy with insulin glargine (GLAR) and metformin (MET) - a proof-of-concept study. Diabetes Care 2010;33:1509-1515
63. Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638-2643
64. Raz I, Chen Y, Wu M, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 2008;24:537-550
65. Scott R, Loeys T, Davies MJ, Engel SS. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008;10:959-969
66. Nauck MA, Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9:194-205
67. Seck T, Nauck MA, Sheng D, et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract 2010;64:562-576
68. Bergenstal RM, Wysham C, Macconell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010. [Epub ahead of print]
69. Pratley RE, Nauck M, Bailey T, et al.; for the 1860-LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin in patients with type 2 diabetes inadequately controlled on metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010;375:1447-1456
70. Schwarz B, Gouveia M, Chen J, et al. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy. Diabetes Obes Metab 2008;10(Suppl 1):43-55
71. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Pharmacologic treatment of diabetes. Can J Diabetes 2008;32(Suppl 1):S53-61
72. Sibal L, Home PD. Management of type 2 diabetes: NICE guidelines. Clin Med 2009;9:353-357
73. Goldstein BJ, Feinglos MN, Lunceford JK, et al.; Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979-1987
74. Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Curr Med Res Opin 2009;25:569-583
75. Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:442-451
76. Holstein A, Stumvoll M. Contraindications can damage your health - is metformin a case in point? Diabetologia 2005;48:2454-2459
77. Engel SS, Williams-Herman DE, Golm GT, et al. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract 2010;64:984-990